Q32 Bio Inc. Common Stock (QTTB)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 22
- Market Cap
- $462M
About Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
SentiSense also tracks daily options readings for Q32 Bio Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Q32 Bio Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.